TriangleNCT00644189 · OUTCOME
All Phase I Participants: Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- percentage of participants
- Interval / dispersion
- 90% Confidence Interval
- Time frame
- at 17 months
What was measured
Determine the overall survival rate among all phase I trial participants who are treated with any of the 4 dose levels of oral clofarabine (1mg, 2mg, 4mg, or 3mg)
Analysis population: Phase I participants only
Groups in this outcome
Phase I
Clofarabine: Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
| Group | Source count |
|---|---|
| Phase I | 30 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase I | 75 | Not reported | 62 | 89 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 62
- upper Limit
- 89
- value
- 75
- denoms
- counts
- group Id
- OG000
- value
- 30
- units
- Participants
- description
- Determine the overall survival rate among all phase I trial participants who are treated with any of the 4 dose levels of oral clofarabine (1mg, 2mg, 4mg, or 3mg)
- dispersion Type
- 90% Confidence Interval
- groups
- description
- Clofarabine: Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
- id
- OG000
- title
- Phase I
- param Type
- MEAN
- population Description
- Phase I participants only
- reporting Status
- POSTED
- time Frame
- at 17 months
- title
- All Phase I Participants: Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice